Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer
Clinical trial NCT04560127 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04560127
- Sponsor
- Peking Union Medical College Hospital
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-09-23
- Primary completion
- 2025-12-31
- Enrollment
- 20
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.